Iowa University researchers at its Children’s Hospital led the effort that found a new target. According to the Iowa Carver College of Medicine, to date, efforts by researchers focused on the inflammatory process while the new approach alleviates the root cause of C3 Glomerulopathy that is found in the complement system, a crucial part of the immune defense.
A deficiency in complement proteins creates vulnerability to infections and autoimmune diseases.
The End Result
The investigation of pegcetavoplan found a 68% reduction of protein in the urine of participants plus stabilization of kidney function. Furthermore, 67% of those tested achieved complete remission and 72% were found to be clear of disease activity. A total of 122 centers involving 124 patients in 19 countries participated in the trial.
Pegcetacoplan had been approved earlier in 2025 by the FDA as the first effective treatment for children over twelve years who have been diagnosed with C3G and IC-MPGN and is the first treatment for patients twelve years or older diagnosed with C3G and closely related IC-MPGN kidney disease.
The Latest Advance
Professor Richard Smith who is an expert in kidney disease that is complement related, led the most recent advance involving the complement system. People from all over the world have willingly traveled to Iowa as the team has earned the trust of patients who wish to receive care at the University’s Renal Center. It was the research conducted at Dr. Smith’s lab suggesting that activation of the complement pathway may lead to effective treatment. This motivated the UI researchers to convert this knowledge into therapies that they tested and confirmed would inhibit complement activation.
Previous treatments relied on anti-inflammatory drugs or even drugs that focused incorrectly on the complement pathway. Now the new medication blocks malfunctioning parts of the complement system.
Pegcetacoplan was approved earlier this year to treat adults diagnosed with C3G and also inhibits the complement system. According to Dr. Nester, it was a long road but the impact on patients is profound.
